HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Collaboration in academia designed to increase return on research investments
-
- AACR launches immunology journal
- ASCO appoints chief medical officer
- Breakthroughs in T-cell physiology, new oral anticoagulants among highlights of 2012 Joseph R. Bertino, MD; Harry S. Jacob, MD, DHC
- Cuba on ‘cutting edge’ of many areas in health care
- Foundation honors St. Jude researcher
- Foundation names award recipients
- Scientist receives abstract award
- ASCO, ASH: ‘Fiscal cliff’ legislation only provides temporary reprieve
-
- FDA cautions against Pradaxa in patients with mechanical prosthetic heart valves
- A 59-year-old man with hepatitis B reactivation during treatment for Hodgkin’s lymphoma
- FDA approves Iclusig to treat CML, PH+ ALL
- FDA expands Zytiga indication
- Myelofibrosis stem cells may exist in spleens of patients
- Addition of abiraterone acetate to prednisone improved fatigue in patients with prostate cancer
- Additional PET/CT scans failed to provide clinical benefit in head, neck cancer
- BCC on lip found slightly more common among women than men
-
- BMI did not influence outcomes of adjuvant therapy for early-stage breast cancer
- BRAF mutation in serous ovarian cancers associated with improved prognosis
- BRAF mutation increased mortality risk in melanoma, colorectal cancer patients
- Cisplatin increased VTE risk in patients with advanced solid tumors
- Combination imaging technique detected recurrence in sarcoma
- Metformin prolonged survival in patients with ovarian cancer
- CT clearance of spine may increase breast cancer risk in pediatric trauma patients
- Delay in breast cancer treatment decreased survival rate of late-stage patients
-
- Drug screening identified possible combination therapies for mutant BRAF, RAS melanomas
- Early molecular response may predict outcomes for nilotinib in CML
- EBNA-1 transfer shows promise in avoiding Epstein-Barr virus reactivation
- Fibulin-3 biomarker may detect early-stage pleural mesothelioma
- Gene variations predicted lung cancer susceptibility in Asian women
- Irradiation after radical prostatectomy improved PFS
- Melanoma, nonmelanoma risk lower among vitiligo patients
- Moderately expressed protein carried poor prognosis for breast cancer
-
- Obesity increases surgery time, cost in patients with lung cancer
- Opioids overprescribed to patients following dermatologic surgery
- Pain significantly predicted SCC compared with BCC
- Pathway found in human lymphoma shows potential for novel blood cancer treatments
- Physicians order frequent diagnostic imaging procedures for pediatric patients
- Postmenopausal breast cancer survivors more likely to develop diabetes
- Researchers use genetics to refine model for assessing skin cancer risk
- Rituximab failed to improve survival after stem cell transplant for DLBCL
-
- Second-generation stent reduced thrombosis, all-cause mortality in diabetics
- Sentinel lymph node biopsy benefited cutaneous melanoma patients
- Sorafenib combined with carboplatin, paclitaxel failed to improve OS in advanced melanoma
- Surgical wait times increased in Medicare patients with breast cancer
- Total retinoblastoma treatment cost linked to tumor grade, family income
- Trametinib showed minimal clinical activity in BRAF-mutated melanoma
- Abnormal hematological indices linked to decompensation, poor response in patients with cirrhosis, HCV
- Addition of rituximab to chemotherapy improved survival in follicular lymphoma
-
- Addition of Zolinza to HSCT conditioning could reduce GVHD
- Adjuvant bevacizumab failed to improve survival outcomes in triple-negative disease
- Adjuvant chemotherapy improved survival after breast cancer recurrence
- Cognitive problems may occur before chemotherapy begins
- Double UCB transplant did not improve survival in children
- Eltrombopag maintained efficacy after cessation in immune thrombocytopenia
- Genetic factors associated with heart failure in patients who underwent HCT
- Genome sequencing identified HER-2 mutations as therapy targets
-
- Novel assay shows promise in heparin-induced thrombocytopenia
- Novel TKI increased durable response in CML, ALL patients with deadly mutations
- Novel TKI may be safe, effective for subset of patients with treatment-resistant AML
- Omission of daunorubicin did not reduce survival among children with ALL
- Oral rivaroxaban superior to standard therapy for VTE
- Patients with hepatitis at greater risk for non-Hodgkin's lymphoma
- Proteasome inhibitor shows promise in multiple myeloma
- Subclonal driver mutations shortened remission period in CLL
-
- Two years of adjuvant trastuzumab yielded no extra benefit